Back to Search
Start Over
1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS).
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS1084-S1084. 1p. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159078078
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.1294